PTC Therapeutics Inc.

NASDAQ: PTCT · Real-Time Price · USD
48.58
-0.12 (-0.25%)
At close: Aug 15, 2025, 12:40 PM

PTC Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
806.78M 937.82M 698.8M 538.59M
Cost of Revenue
57.4M 288.12M 44.68M 32.33M
Gross Profit
749.38M 649.7M 654.12M 506.26M
Operating Income
-302.57M -349.4M -439.93M -374.94M
Interest Income
n/a n/a n/a n/a
Pretax Income
-363.12M -696.11M -587.49M -518.34M
Net Income
-363.3M -626.6M -559.02M -523.9M
Selling & General & Admin
300.91M 332.54M 326M 285.77M
Research & Development
534.48M 666.56M 651.5M 540.68M
Other Expenses
216.56M -353.83M 116.55M 54.75M
Operating Expenses
1.05B 645.27M 1.09B 881.21M
Interest Expense
166.99M 129.18M 90.87M 86.02M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
1.11B 1.38B 1.14B 913.54M
Income Tax Expense
176K -69.51M -28.47M 5.56M
Shares Outstanding (Basic)
76.85M 74.84M 71.73M 70.47M
Shares Outstanding (Diluted)
76.85M 74.84M 71.73M 70.47M
EPS (Basic)
-4.73 -8.37 -7.79 -7.43
EPS (Diluted)
-4.73 -8.37 -7.79 -7.43
EBITDA
-120.46M -330.34M -367.78M -368.18M
EBIT
-196.13M -566.93M -496.62M -432.32M
Depreciation & Amortization
75.66M 236.59M 128.84M 64.13M